- |||||||||| KB407 / Krystal Biotech
Enrollment change, Trial withdrawal: A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis (clinicaltrials.gov) - Aug 14, 2023
P1, N=0, Withdrawn,
KB407 is able to transduce and deliver full-length CFTR to clinically relevant airway epithelial cell populations in vitro, including patient-derived apical-out organoids, supporting future clinical development of KB407 as an inhaled therapeutic for patients with CF. N=13 --> 0 | Recruiting --> Withdrawn
- |||||||||| KB407 / Krystal Biotech
Enrollment change, Trial completion date, Trial primary completion date: CORAL-1: A Study Assessing KB407 for the Treatment of Cystic Fibrosis (clinicaltrials.gov) - Jul 28, 2023
P1, N=12, Recruiting,
N=13 --> 0 | Recruiting --> Withdrawn N=20 --> 12 | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024
- |||||||||| KB407 / Krystal Biotech
Enrollment open, Trial initiation date: CORAL-1: A Study Assessing KB407 for the Treatment of Cystic Fibrosis (clinicaltrials.gov) - Jun 5, 2023
P1, N=20, Recruiting,
N=20 --> 12 | Trial completion date: Mar 2024 --> Jul 2024 | Trial primary completion date: Mar 2024 --> Jul 2024 Not yet recruiting --> Recruiting | Initiation date: Nov 2022 --> Jun 2023
- |||||||||| KB407 / Krystal Biotech
Respiratory cell-type affinity and absolute CFTR expression in the primate airway upon nebulization of KB407 (119 A) - Aug 5, 2022 - Abstract #NACFC2022NACFC_448;
Not yet recruiting --> Recruiting | Initiation date: Nov 2022 --> Jun 2023 Taken together, these data indicate that KB407 capablytransduces multiple cell types that contribute to native CFTR function inprimate airways and expresses the transgene at physiologically relevantlevels, providing further support for the potential of KB407 as an inhalablegene therapy for the treatment of CF.
- |||||||||| KB407 / Krystal Biotech
Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date: A Study of Inhaled KB407 for the Treatment of Cystic Fibrosis (clinicaltrials.gov) - Jun 8, 2022
P1, N=13, Recruiting,
Taken together, these data indicate that KB407 capablytransduces multiple cell types that contribute to native CFTR function inprimate airways and expresses the transgene at physiologically relevantlevels, providing further support for the potential of KB407 as an inhalablegene therapy for the treatment of CF. Not yet recruiting --> Recruiting | Trial completion date: May 2022 --> Oct 2024 | Initiation date: Oct 2021 --> Mar 2022 | Trial primary completion date: Mar 2022 --> Jul 2024
- |||||||||| KB407 / Krystal Biotech
[VIRTUAL] Nonclinical pharmacology of nebulized KB407 for the treatment of cystic fibrosis () - Oct 19, 2021 - Abstract #NACFCI2021NACFC_I_1007;
Not yet recruiting --> Recruiting | Trial completion date: May 2022 --> Oct 2024 | Initiation date: Oct 2021 --> Mar 2022 | Trial primary completion date: Mar 2022 --> Jul 2024 These data support repeated application of KB407 as a broadly applicable gene therapy for the treatment of CF.
|
